Showing posts with label testing. Show all posts
Showing posts with label testing. Show all posts

Wednesday, June 3, 2020

Testing, Testing, (Phase) 1-2-3: Legal Considerations for Clinical Trials of Potential COVID-19 Vaccines

"In the race to develop a Coronavirus Disease 2019 (COVID-19) vaccine, several pharmaceutical companies, governments, and educational institutions around the world have begun testing their potential COVID-19 vaccines in clinical trials. Clinical trials are used to assess whether a new pharmaceutical product, such as a vaccine, is safe for humans and effective in achieving its intended purpose. Companies must generally test new pharmaceutical products on humans through clinical trials to obtain U.S. Food and Drug Administration (FDA) approval to market the product. But using human subjects to test these novel products exposes them to unknown health and safety risks, raising ethical considerations for FDA and for the sponsors and Institutional Review Boards (IRBs) overseeing the investigations. These stakeholders—sponsors, IRBs, and FDA—aim to balance the need to ensure that the product is safe and effective against the desire to bring the product to market quickly, tensions that are heightened during a worldwide pandemic. Existing law requires FDA and IRBs to weigh these considerations when evaluating proposed clinical trial designs for COVID-19 vaccines.

This Sidebar describes the legal and regulatory framework that governs clinical trials for pharmaceutical products, such as vaccines, and some avenues researchers and Congress may consider for accelerating that process during the COVID-19 pandemic. (For ease of reference, this Sidebar uses the term drugs includes both traditional drugs and biological products, including vaccines.).."
Testing and clinical trails

Friday, April 17, 2020

U.S. Lags the world in testing, leads the world in COVID-19 cases

"The first case of COVID-19 in the United States was diagnosed in Washington state on January 20, 2020i . After 12 weeks, and the appearance of over 600,000 cases of COVID-19 and over 25,000 deaths, the United States still lacks a national testing strategy to reliably and consistently test patients across the country. Instead, states have been forced to respond with limited federal support, leaving a patchwork of testing efforts across the country, limited data on the spread of the disease, and scarce supplies for testing and protection of health care workers.

As of April 14, more than 150,000 people are being tested each day, and more than 2.8 million tests have been performed. This is far below the amount of testing per capita that has been done in other countries..."
COVID-19 and testing

Thursday, December 10, 2009

The Nation's Report Card: Trial Urban District Assessment Mathematics 2009
"Scores for most districts higher than in 2003, but few make gains since 2007

Representative samples of fourth- and eighth-grade public school students from 18 urban districts participated in the 2009 assessment. Eleven of the districts also participated in earlier assessment years, and seven districts participated for the first time in 2009. Between 1,800 and 4,300 fourth- and eighth-graders were assessed in each district.

In comparison to 2007, average mathematics scores for students in large cities increased in 2009 at both grades 4 and 8; however, only two participating districts at each grade showed gains. Scores were higher in 2009 for Boston and the District of Columbia at grade 4, and for Austin and San Diego at grade 8. No districts showed a decline in scores at either grade.

In comparison to 2003, scores for students in large cities were higher in 2009 at both grades 4 and 8. Increases in scores were also seen across most urban districts that participated in both years, except in Charlotte at grade 4 and in Cleveland at grades 4 and 8, where there were no significant changes."